A Multi-level Intervention to Increase Access and Use of the Patient Portal

January 3, 2024 updated by: Yale University
The purpose of the study is to develop and evaluate a multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).

Study Overview

Detailed Description

There are 2 phases in this study, developing and optimizing the intervention in Phase 1 using qualitative methods. In Phase 2, a pilot study will be conducted at two CHCs to evaluate the effect of the intervention on patient portal use, patient engagement with care, and clinical outcomes in adults with type 2 diabetes. For the purpose of this registration, Phase 2 of the study will be described.

Using a within subjects, pre-post design the investigator will pilot MAP in an anticipated 30 adults with T2D who are not using the portal. Data will be collected at baseline, 3, and 6 months. The investigators will evaluate the feasibility of MAP using an established framework (acceptability, demand, implementation, adaptation, and integration.

The intervention will consist of the following:

  1. provide free access to tablets and internet (material circumstances);
  2. technology training and ongoing support (psychosocial factors);
  3. assess social determinants of health and refer to community resources (material circumstances);
  4. support diabetes self-management behaviors and refer to clinic services (behavioral and biological factors).

MAP will be delivered by community health workers (CHW) and nurses already embedded in CHCs (healthcare system). The 3-month intervention is thoughtfully sequenced to first have CHWs address patient portal access (tablet, home internet), and then move on to patient mastery of the tablet and portal functionality. Next, CHWs will assess social determinants of health using an established measure and connect the participant to relevant community resources (e.g., SNAP benefits). It is anticipated that participants will have 4-6 individual sessions with the CHW, approximately 30 minutes each, followed by ongoing technology support as needed.

Next, the clinic nurse will proactively contact the participant via the portal to provide diabetes self-management support. The nurse will begin by assessing participant behaviors and will then work with the participant to co-create a plan to help with diabetes self-management. The plan will include referral to relevant ancillary clinic services as needed (e.g., DSM education [DSME], nutritionist, obtaining a glucose meter). Participants will be instructed and encouraged to upload blood glucose data and communicate with the nurse and their health care provider via the portal, both of which have been shown to improve glycemic control. The nurse will work with each patient to individualize DSMS behavioral targets, considering the following priorities: use of the portal, attendance at appointments, uploading of blood glucose data to the portal, medication refills and adherence, and lifestyle and emotional factors. It is anticipated that nurses will communicate with patients via the portal at least twice weekly during the first month followed by ongoing DSMS as needed. In-person or telehealth sessions will be scheduled as needed. However, the exact sequence, timing, and length of sessions will be participant driven. For example, a participant who learns the portal quickly may proceed at a faster rate, or a participant who already uploads glucose data may skip that step.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Recruiting
        • Fair Haven Community Health Center
      • Norwalk, Connecticut, United States, 06854
        • Recruiting
        • Norwalk Community Health Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Established patient of one of the partner CHCs
  • Age > 18 years
  • Diagnosed with T2D >6 months
  • Able to read in English or Spanish
  • Not using the patient portal
  • A1c >7.5%

Exclusion Criteria:

  • Cognitive impairment (≥3 errors on the Six Item Screener for cognitive impairment in clinical research [SIS]) (Callahan et al. 2002) as they will have difficulty in completing the study requirements
  • Gestational diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Use of patient portal for diabetes management
A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Usage of Portal
Time Frame: Monthly for 6 months
Frequency. Mean portal login days/per month will be calculated using the EMR system
Monthly for 6 months
Change in A1C value
Time Frame: Baseline, 3 months and 6 months
The A1C value will be assessed via fingerprick point of care A1c kits.
Baseline, 3 months and 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Portal messaging
Time Frame: Monthly for 6 months
Number of messages sent/received total and per month
Monthly for 6 months
Tracking biometric data
Time Frame: Monthly for 6 months
Number of views of test results, blood glucose uploads total and per month
Monthly for 6 months
Health care engagement - positive
Time Frame: Baseline, 3 months, and 6 months
Number of medication refills, clinic appointments, use of community resources over previous 3 months
Baseline, 3 months, and 6 months
Summary of Self-Care in Diabetes Survey
Time Frame: Baseline, 3 months, and 6 months
Diet, exercise, medication, and blood glucose self-management over past 7 days (score range 0-7, with higher scores indicating better self-care)
Baseline, 3 months, and 6 months
Diabetes Self-Efficacy
Time Frame: Baseline, 3 months, 6 months
Self-confidence in diabetes self-management tasks (score range from 0-10 with higher scores indicating better diabetes self-efficacy)
Baseline, 3 months, 6 months
Health care engagement - negative
Time Frame: Baseline, 3 months, 6 months
Number of ER visits and hospitalizations over the previous 3 months
Baseline, 3 months, 6 months
Health Care Climate Questionnaire
Time Frame: Baseline, 3 months, 6 months
Perception of support by health care providers with higher scores indicating more perceived support
Baseline, 3 months, 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Robin Whittemore, PhD, APRN, Yale University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 3, 2022

Primary Completion (Estimated)

May 15, 2024

Study Completion (Estimated)

June 15, 2024

Study Registration Dates

First Submitted

December 14, 2021

First Submitted That Met QC Criteria

January 5, 2022

First Posted (Actual)

January 6, 2022

Study Record Updates

Last Update Posted (Actual)

January 5, 2024

Last Update Submitted That Met QC Criteria

January 3, 2024

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 2000031753
  • R21MD016949-01 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Use of patient portal for diabetes management

3
Subscribe